Foghorn Therapeutics Inc (FHTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.13 (-1.67%), Market cap $0.22B, 52-week low–high $3.53 ~ $6.68.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhib
Financial statements, price targets, institutional (13F) holdings and related news for Foghorn Therapeutics Inc are updated in real time on BlackAll Trade.
Foghorn Therapeutics Inc trades at $4.13 (-1.67%). Real-time quotes and charts are available on BlackAll Trade.
Foghorn Therapeutics Inc has a market cap of about $0.22B.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulato